Fagron Shareholders Approve Key Resolutions at AGM
Fagron, a leading entity in the realm of pharmaceutical compounding, conducted its annual general meeting with great success where all proposed resolutions received the nod from its shareholders. This meeting marks a significant moment for Fagron as it seeks to further enhance its operations and uphold its commitment to personalized medicine.
Key Resolutions Approved
Among the important decisions taken during the meeting were the endorsement of Fagron's annual financial statements and a proposal for a dividend of €0.35 per share pertaining to the fiscal year 2024. Additionally, the remuneration policy was solidified, alongside the ratification of the statutory auditor for the years spanning from 2025 to 2027. A notable highlight was the reappointment of Ann Desender BV as an independent non-executive director, a role she will continue to hold until the annual meeting in 2029.
Comprehensive Meeting Documentation
All pertinent documents related to the meetings have been uploaded on Fagron’s official website, ensuring transparency and accessibility for all shareholders. The minutes of the meetings will also be made available online for review.
Dividend Calendar Information
The board outlined a clear schedule concerning the dividend payments to keep shareholders well-informed:
- Ex-dividend date: 19 May 2025
- Record date: 20 May 2025
- Payment date: 21 May 2025
Further Information for Investors
For additional inquiries, stakeholders are invited to reach out via email for more information on business operations and investment opportunities. Fagron is dedicated to maintaining open lines of communication with its investors.
About Fagron
Fagron stands out as a major player in pharmaceutical compounding on a global scale, focusing on personalized medicine. With operations in over 30 countries, Fagron delivers tailored medicinal solutions to hospitals, pharmacies, and clinics, ensuring that patient needs are met with precision and care.
Based in Belgium, Fagron NV is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. The Dutch entity, Fagron BV, manages the operational arms of the company from its headquarters in Rotterdam, underscoring Fagron's strong European presence in the market.
Frequently Asked Questions
What major resolutions did Fagron shareholders approve?
Shareholders approved the annual financial statements, a dividend proposal, remuneration policy, and auditor appointments.
When is the payment date for Fagron's dividend?
The payment date for the approved dividend is scheduled for May 21, 2025.
How does Fagron ensure shareholder communication?
Fagron maintains transparency by providing meeting documents and minutes on their website and encouraging direct communication through email.
What is Fagron's main business focus?
Fagron specializes in pharmaceutical compounding, primarily providing personalized medicine to healthcare facilities across multiple countries.
Where is Fagron's headquarters located?
Fagron NV is headquartered in Nazareth, Belgium, with operational management conducted by Fagron BV based in Rotterdam, the Netherlands.
